Amphenol's stock plummeted 5.01% intraday on Monday, reflecting significant selling pressure.

The decline follows BofA Global Research's decision to remove Amphenol from its "US 1 List," a collection of the firm's best investment ideas, which likely triggered negative sentiment among investors.

Additionally, ongoing concerns about margin dilution from the consolidation of CCS into Amphenol's financial results continue to weigh on the stock. While CCS consolidation is expected to contribute approximately $9 billion in revenue, its contribution to adjusted earnings per share is only about $0.02 for the quarter, highlighting investor worries about the dilutive impact on overall profit margins.